Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development

BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages

The incidence and death rate of pancreatic ductal adenocarcinoma (PDAC) have increased in recent years, therefore the identification of novel targets for treatment is extremely important. Interactions between cancer and stromal cells are critically involved in tumour formation and development of metastasis. Here we report that PDAC cells secrete BAG3, which binds and activates macrophages, indu...

Pancreatic ductal adenocarcinoma staging

In addition to clinical history and evaluations, the results of laboratory tests and imaging studies help clinicians in determining treatment strategies. Imaging plays a central role in the management of oncology patients including the initial diagnosis, staging, and follow-up to assess treatment response. Historically, radiologists have relied on free-style dictations to convey the results of ...

Pancreatic Ductal Adenocarcinoma Signalling

Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas. PDAC is an aggressive and difficult malignancy to treat. Complete surgical removal of the tumor remains the only chance for cure, however 80-90% of patients have disease that is surgically incurable at the time of clinical presentation (15). Despite our advancing knowledge of the tumor biology of PDAC, improv...

Mimics of pancreatic ductal adenocarcinoma

Several uncommon primary pancreatic tumors, inflammatory conditions, metastasis to the pancreas and peripancreatic masses can mimic the appearance of pancreatic ductal adenocarcinoma (PDA). Differentiation between these lesions and PDA can be challenging, due to the overlap in imaging features; however, familiarity with their typical imaging features and clinical presentation may be helpful in ...